Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2019 June;74(3) > Minerva Chirurgica 2019 June;74(3):253-62

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  CONTROVERSIES IN PANCREATIC SURGERY 

Minerva Chirurgica 2019 June;74(3):253-62

DOI: 10.23736/S0026-4733.18.07972-5

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Surgical resection of liver metastasis in pancreatic and periampullary carcinoma

Victor LOPEZ-LOPEZ 1, Ricardo ROBLES-CAMPOS 1 , Asunción LÓPEZ-CONESA 1, Roberto BRUSADIN 1, Guillermo CARBONEL 2, Alvaro GOMEZ-RUIZ 1, Juan J. RUIZ 1, Pascual PARRILLA 1

1 Department of Surgery, Virgen de la Arrixaca Clinic and University Hospital, Murcia, Spain; 2 Department of Radiology, Virgen de la Arrixaca Clinic and University Hospital, Murcia, Spain



INTRODUCTION: Once liver metastases in pancreatic and periampullary carcinoma are diagnosed, guidelines do not recommend resection of the primary tumor. In this stage of the disease, therapeutic regimes with chemotherapy are the standard treatment. However, it is unclear whether combinations of extensive surgery and novel chemotherapy treatments confer a survival benefit in selected patients.
EVIDENCE ACQUISITION: We provide a systematic review about liver metastases in pancreatic and periampullary carcinoma treated by surgery utilizing EMBASE, Medline/PubMed, Cochrane and Scopus databases according to PRISMA guidelines.
EVIDENCE SYNTHESIS: In pancreatic and periampullary carcinoma, the number of lesions that can be resected includes a mean or median of 1-3; the size of the lesions should not exceed 3 cm and the most frequent surgical technique used were wedge or atypical resections. Overall morbidity and mortality after liver resection from pancreatic tumors were 0-68% and 0-9.1%, respectively, and from periampullary carcinomas were 0-82% and 0-21%, respectively. Considering both types of carcinomas, the rate of recurrence was up to 91%. Median overall survival ranged from 5.5 to 16.6 months for liver metastases from pancreas carcinoma, and from 5 to 23 months for periampullary carcinoma, with better prognosis for duodenal carcinomas.
CONCLUSIONS: Perioperative chemotherapy is the cornerstone of treatment in patients with liver metastasis from pancreatic and periampullary carcinoma. Liver resection from early liver metastases could be acceptable in selected patients with oligometastatic disease and small single lesions taking into account the individual risk of complications.


KEY WORDS: Liver neoplasms - Pancreatic ductal carcinoma - Hepatectomy - Survival rate

top of page